Price List - Vybrique - Phosphodiesterase-5 Inhibitors - Erectile Dysfunction.xlsx
XLSX spreadsheet 47 KB Posted
- Solicitation number
- HT9402-26-Q-9202
- Issued by
-
Defense Health Agency
About this file
This is a pricing template for pharmaceutical quotes related to the Department of War Uniform Formulary review process. The file contains pricing appendices for Vybrique (Phosphodiesterase-5 Inhibitors for Erectile Dysfunction) across multiple newly approved drug entries, with quotes due by March 26, 2026, for a P&T Committee meeting scheduled for May 6-7, 2026. The template includes sections for Blanket Purchase Agreement (BPA) pricing for Military Treatment Facilities and Mail Order pharmacies, with two formulary scenarios: Uniform Formulary and Non-Formulary categories. Manufacturers are required to submit pricing for price per NDC package size and price per unit across both scenarios.
The document also contains Additional Discount Program (ADP) appendices using two pricing methodologies: non-FAMP discount and Wholesale Acquisition Cost (WAC) discount approaches. For the non-FAMP method, manufacturers must provide the Non-FAMP price, additional offered refund percentage, current Federal Ceiling Price, and standard refund calculations for Tier 2 and Tier 3 classifications. For the WAC method, manufacturers must provide WAC pricing and WAC discount percentages. The file emphasizes that manufacturers must submit the Quote Submission Checklist, fully executed signature pages, and that price per unit of measure must be consistent across all package sizes within a given dispensing venue. Agents not receiving submitted or selected quotes may be designated as non-step preferred under the Step Therapy Addendum, and Prior Authorization may apply to any recommended agents.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List - Cardamyst - Calcium Channel Blocking Agents - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Myqorzo - Cardiovascular Agents Miscellaneous - NA.xlsx | XLSX spreadsheet | |
| Price List - Sdamlo - Calcium Channel Blocking Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Pivya -Antibiotics - Beta-lactams.xlsx | XLSX spreadsheet | |
| RFQ HT9402-26-Q-9202 NAD.pdf | ||
| Price List - Zycubo - Electrolyte-Mineral-Trace Element Replacement - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - Ontralfy - Skeletal Muscle Relaxants and Combinations - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263PDEDG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263PDEDG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DOD Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 |
| DOD Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOW Uniform Formulary Class: | PHOSPHODIESTERASE-5 INHIBITORS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | ERECTILE DYSFUNCTION | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263PDEDG1T21M | Tier 2 | 1 or more | |
| 263PDEDG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .